
Understand the weight-loss and testosterone evidence, why SHBG matters, and how metabolic health fits into a full clinical assessment.

This review draws on the EAU male-hypogonadism guideline, updated in October 2026. It is an analysis of clinical guidance rather than a report on a newly completed experiment. The guideline brings together evidence about diagnosis, associated health conditions and treatment decisions.
The weight-loss estimate comes from meta-analyses summarized within that guidance. Meta-analyses combine results from multiple studies. The figure therefore represents an average across the evidence reviewed rather than the outcome of one standardized weight-loss program.
That distinction sets the main limit on interpretation: the average does not predict an individual man's response or establish that symptoms will improve. A change in a hormone measurement is not automatically the same as a change in how someone feels.
This article provides general education, not personal medical advice or a diagnosis. A qualified clinician should interpret individual symptoms and laboratory results. Decisions about investigation or treatment belong within that assessment.
The EAU describes the average increase of about 1-2 nmol/L as small. Turning that finding into a promise of a dramatic hormone increase would go beyond the evidence. It would also confuse a research outcome with a clinical decision.
The guideline reports that testosterone increases are associated with the amount of weight lost. It also links the effects of physical activity to exercise duration and weight reduction. These findings support a relationship between changes in weight and hormone measurements rather than a universal response to any particular activity.
Clinically, an increase and a diagnosis answer different questions. The increase describes movement in a laboratory value. Diagnosis asks whether compatible symptoms occur alongside confirmed low testosterone and what explains that pattern.
A higher result after weight loss therefore belongs in the same assessment as the original result. Its meaning depends on the wider clinical picture rather than on whether the number moved upward.
SHBG stands for sex hormone-binding globulin. The EAU lists obesity and insulin resistance among the conditions associated with lower SHBG. It also includes type 2 diabetes and metabolic syndrome.
Because SHBG affects the interpretation of total testosterone, the guideline recommends considering its measurement when it may be altered. Free-testosterone assessment can then help estimate androgen status. This is a reason to interpret related biomarkers together rather than treat each result as a separate verdict.
The guideline identifies equilibrium dialysis as the most accurate method for measuring free testosterone. It also describes calculating free testosterone using SHBG and albumin. The recommendation is to use this additional assessment when indicated, not to replace clinical judgment with another isolated number.
Testostra's explanation of reading hormone tests together provides related context for these distinctions.
The EAU also summarizes substantial weight regain during longer follow-up. It cites 60-86% of lost weight regained by three years and 75-121% by five years in the evidence reviewed.
Those percentages describe the amount of lost weight regained. They do not describe the percentage of men who regained weight. They are also not forecasts for an individual reader.
For interpretation, the useful distinction is between an initial change and a sustained outcome. Weight-loss evidence should be read with attention to follow-up rather than only the first reported improvement. Maintenance deserves a place in the discussion without becoming a reason to discourage weight management.
The EAU describes low testosterone as common among men with obesity. It associates hypogonadism with greater fat mass and lower lean mass. It also notes associations between low testosterone and visceral fat accumulation or fat deposition in the liver and muscle.
This makes a simple one-direction explanation incomplete. Body composition and hormone status can influence one another. Metabolic illness and other health conditions can also affect hormone regulation.
The guideline uses the term functional hypogonadism for some cases associated with other health conditions or potentially reversible influences. This differs from an identified structural problem affecting the pituitary or testes. Crucially, functional hypogonadism is a diagnosis of exclusion.
That means clinicians investigate organic causes before settling on a functional explanation. Body size alone does not make that distinction. Nor does a history of weight gain establish why a testosterone result is low.
The EAU's possible causes include pituitary or testicular disorders and chronic systemic disease. Its list also includes metabolic disorders and medicines such as opioids and glucocorticoids. These possibilities explain why medication history and wider health assessment matter.
For the average reader, the key point is that the same visible concern can sit within different clinical patterns. One man's assessment may center on metabolic health. Another may require investigation of a different cause, even when excess body fat is also present.
This is the value of putting weight within the broader health picture. Weight is relevant information, but it is not a complete explanation.
The practical message is not simply to pursue a larger testosterone number. It is to establish what the measurements mean and identify which contributing factors are relevant. Weight management and medical assessment are compatible parts of that process.
The EAU's diagnostic approach combines compatible signs or symptoms with consistently low testosterone. It specifies morning fasting total-testosterone testing using a reliable assay. Repeat measurement comes before testosterone therapy.
Confirmation establishes whether the low result persists under the recommended testing conditions. Investigation then addresses why it is low. These are connected tasks, but one does not replace the other.
A useful appointment question is: “Has the hormone pattern been confirmed, and what still needs explaining?” Testostra's discussion of the reason for confirming a low result adds context to that distinction.
The guideline recommends reviewing associated conditions and medicines. It also supports SHBG and calculated free testosterone when appropriate. Together, these considerations create a fuller picture than body weight or total testosterone alone.
Questions that follow directly from this evidence include:
These are questions for qualified care rather than a checklist for self-diagnosis. Personal decisions depend on the findings from that assessment.
For men with hypogonadism who are overweight or obese, the EAU recommends lifestyle improvement and weight reduction before testosterone therapy. It also recommends addressing relevant accompanying conditions and medicines that may impair testosterone production where possible.
The reasonable educational takeaway is gradual, sustainable weight management when excess weight is contributing. The guideline's summary does not supply a personal calorie target or a universal exercise prescription. Those details require an individual discussion rather than a hormone-focused formula.
Importantly, the recommendation is about the order and context of care. It is not a blanket prohibition on testosterone therapy for men with obesity. It also does not require postponing investigation of other causes while weight changes are pursued.
As new studies and future guideline revisions appear, the most useful data will connect sustained weight change with a fuller hormone assessment. Reporting total testosterone alongside SHBG and free testosterone would help clarify what changed. Including symptoms would make the results more clinically informative.
Longer follow-up is especially worth watching because the EAU's existing synthesis identifies weight regain as an important issue. Future evidence should distinguish an early laboratory improvement from a sustained clinical outcome. It should also make clear which populations were studied and how other causes of hypogonadism were assessed.
These are priorities for interpreting future evidence, not announcements of a scheduled trial or release. A larger headline increase would be less useful than a clearer account of who benefited and whether that benefit lasted.
For now, the evidence supports addressing relevant weight and metabolic factors while preserving a full clinical assessment. The goal is a better explanation of the hormone pattern rather than a single explanation applied to every man.
After the weight-loss evidence comes the question of how a hormone result should be read, which Testostra addresses through clear reporting on testing and biomarkers. For men unsure how total testosterone relates to free testosterone and SHBG, that coverage supplies context for medical discussions while leaving diagnosis and treatment decisions with qualified clinicians.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra